Lea Ruge

Lea Ruge

Auto-generated profile, based on publicly available information

Lea Ruge

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Lung Cancer Group Cologne (LCGC), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FJFelix John
Felix John
LRLea Ruge
Lea Ruge
MVMalte Verheyen
Malte Verheyen
HSHeather Scharpenseel
Heather Scharpenseel
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
MSMatthias Scheffler
Matthias Scheffler
Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.

25 September 2025 in Lung Cancer
Verified
Journal Article
Closed access
MSMatthias Scheffler
Matthias Scheffler
LTLia Tzala
Lia Tzala
KLKarly Louie
Karly Louie
TPThorsten Persigehl
Thorsten Persigehl
SLSimon Lennartz
Simon Lennartz
JWJürgen Wolf
Jürgen Wolf


17 June 2026
Verified
Other
Open access
FJFelix John
Felix John
LRLea Ruge
Lea Ruge
MVMalte Verheyen
Malte Verheyen
HSHeather Scharpenseel
Heather Scharpenseel
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
MSMatthias Scheffler
Matthias Scheffler
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups

11 August 2026 in Clinical Lung Cancer
Verified
Journal Article
Open access
RRRichard Riedel
Richard Riedel
MVMalte Verheyen
Malte Verheyen
SMSebastian Michels
Sebastian Michels
LRLea Ruge
Lea Ruge
SSSofia Stilianakis
Sofia Stilianakis
FJFelix John
Felix John
Small-cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis and limited therapeutic progress over recent decades. Although PD-L1 inhibitors have modestly improved survival, responses are not durable. There are no predictive biomarkers that would allow for a personalized treatment strategy. Targeting DNA damage repair deficiencies represents a promising treatment strategy in various solid tumors. Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib have demonstrated efficacy in homologous recombination deficiency (HRD)-positive tumors, and preclinical data suggest synergistic activity with immune checkpoint blockade. GUIDANCE is a biomarker-driven, multicenter, single-arm, open-label phase II trial evaluating maintenance therapy with durvalumab and olaparib in patients with advanced or metastatic SCLC without progression after first-line therapy with platinum, etoposide and durvalumab. Patients are prospectively selected for HRD based on homologous recombination repair gene alterations and/or a genomic instability score. Following central prescreening, 29 patients will be enrolled. Patients receive durvalumab (1500 mg every 4 weeks) and olaparib (300 mg twice daily) until progression or unacceptable toxicity. The primary endpoint is progression-free survival (PFS) by RECIST 1.1. Secondary endpoints are overall survival, safety and tolerability. Exploratory analyses include circulating tumor DNA (ctDNA) monitoring of individual TP53 mutations, assessment of SLFN11 expression, and characterization of immune cell composition via multiplex immunohistochemistry. This trial investigates a chemotherapy-free, genomically stratified maintenance strategy targeting both DNA damage repair deficiency and immune evasion in SCLC. By integrating HRD-based patient selection with concurrent PARP and immune checkpoint inhibition, GUIDANCE aims to establish a more individualized therapeutic approach and to generate a signal for further evaluation in biomarker-defined patient populations. Trial registration number EuraCT 2024-512373-27-00.

17 June 2026
Verified
Other
Open access
FJFelix John
Felix John
LRLea Ruge
Lea Ruge
MVMalte Verheyen
Malte Verheyen
HSHeather Scharpenseel
Heather Scharpenseel
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
MSMatthias Scheffler
Matthias Scheffler
Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])